# Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma

> **NCT05000450** · PHASE1,PHASE2 · TERMINATED · sponsor: **Allogene Therapeutics** · enrollment: 6 (actual)

## Conditions studied

- Relapsed/Refractory Multiple Myeloma

## Interventions

- **GENETIC:** ALLO-605
- **BIOLOGICAL:** ALLO-647
- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT05000450
- **Lead sponsor:** Allogene Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-06-06
- **Primary completion:** 2023-10-11
- **Final completion:** 2023-10-11
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Terminated (Halted Prematurely)
- **Last updated:** 2024-06-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05000450

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05000450, "Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05000450. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*